Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.
Eighteen patients with disseminated malignant melanoma were treated with a combination of carboplatinum and cytosine arabinoside. There were 14 males and 4 females with median age of 51 years (range 36-68 years). We observed 4 complete responses (CR) and 3 partial responses (PR). Lung metastases, cutaneous and subcutaneous metastases responded more often, while liver and lymph node metastases did not respond. Two groups of toxicities were observed: gastrointestinal and hematological. Only nine grade 3 toxicities were observed. Response rates and low toxicity we observed during this study warrant its use for patients with disseminated malignant melanoma comparing it in a future studies with DTIC containing regimens.
Jeremic
B
B
KBC Kragujevac, Department of Oncology, Yugoslavia.
Djuric
L
L
Mijatovic
L
L
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006400:Hematocrit; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D010976:Platelet Count / Q000187:drug effects
D003561:Cytarabine; D016190:Carboplatin